Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter to Evaluate Eksigent s Microfluidics Technology

NEW YORK, July 20 – Eksigent Technologies said Friday it had signed a deal with Beckman Coulter to jointly look for ways to incorporate Eksigent’s microfluidics technology into Beckman Coulter’s instruments.

Financial terms of the deal were not disclosed.

Established in May of last year, Eksigent of Livermore, Calif., has developed lab-on-a-chip technology, including pumps, valves, and microfabricated systems. The basis of the technology is the electrokinetic pump, which uses an applied electric field to generate fluid flow and high pressures. 

The company said that its pump can be applied to combinatorial chemistry, sample preparation, heat transfer, microvalving, and actuation.

“We anticipate that Eksigent's technology will enable the development of new instrumentation platforms that provide significant advantages to Beckman Coulter's customers,” Jim Osborne, vice president of Advanced Technology at Beckman Coulter, said in a statement.

Beckman Coulter of Fullerton, Calif., develops instruments and products that help to automate simplify laboratory processes. The company also develops diagnostics.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.